The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $224,941 in first-year total cost, median $75,000.
Most frequent study sections
- Special Emphasis Panel[ZAA1 JJ (01)]3
Most frequent institutions
- MAYO CLINIC ROCHESTER1
- UNIVERSITY OF LOUISVILLE1
- VIRGINIA COMMONWEALTH UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis1U01AA026886-01 | SHAH, VIJAY H.SIMONETTO, DOUGLAS A. | MAYO CLINIC ROCHESTER, MN | $75,000 | ZAA1 |
| 2018 | Pilot Trial UO1 DUR-9281U01AA026934-01 | MCCLAIN, CRAIG J. | UNIVERSITY OF LOUISVILLE, KY | $75,000 | ZAA1 |
| 2018 | Novel Therapies for Alcoholic Hepatitis with Sepsis and for Relapse Prevention1U01AA026966-01 | SANYAL, ARUN J | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $74,941 | ZAA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.